Rural Health
News by Topic: COVID-19
FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability
Federal Register
Jul 29, 2025 - The Food and Drug Administration (FDA) has revoked Emergency Use Authorizations issued to Regeneron Pharmaceuticals, Inc., for REGEN-COV (casirivimab and imdevimab administered together); GlaxoSmithKline LLC for sotrovimab; Eli Lilly and Company for bebtelovimab; and AstraZeneca Pharmaceuticals LP for EVUSHELD (tixagevimab co-packaged with cilgavimab). These revocations are effective December 13, 2024.
Source: Federal Register
Jun 26, 2025 - Notice from the Health Resources and Services
Administration (HRSA) seeking comments on an information
collection regarding a form related to the COVID-19
Provider Relief Fund (PRF) and American Rescue Plan (ARP)
rural payment reporting activities. The information
collection is used to assess if statutory and programmatic
requirements are met; conduct audits; report on findings
with respect to the disbursements of PRF and ARP Rural
payments; and for the program evaluation. Comments are due
by August 25, 2025.
Source: Federal Register